Overview

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Canc

Status:
Not yet recruiting

Trial end date:
2027-05-01

Target enrollment:

Participant gender:

Summary

This study is to compare and evaluate the efficacy and safety of ONO-4538 in combination with ipilimumab and chemotherapy versus chemotherapy in chemotherapy-naïve participants with HER2-negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).

Phase:

Phase 3

Details

Lead Sponsor:

Ono Pharmaceutical Co. Ltd

Treatments:

Capecitabine
Ipilimumab
Nivolumab
Oxaliplatin
Tegafur